Copyright
©The Author(s) 2015.
World J Hepatol. Sep 8, 2015; 7(19): 2220-2228
Published online Sep 8, 2015. doi: 10.4254/wjh.v7.i19.2220
Published online Sep 8, 2015. doi: 10.4254/wjh.v7.i19.2220
Table 2 Logistic regression analysis of factors associated with alpha-fetoprotein ≥ 5 ng/mL before therapy
| Univariate analysis | Multivariate analysis | |||
| Factors | OR (range1) | P | OR (range1) | P |
| Age (1: ≥ 60 yr) | 1.2 (0.96-1.5) | 0.10 | ||
| Gender (1: male) | 1.2 (0.93-1.5) | 0.19 | ||
| HCV genotype (1: type 1) | 0.72 (0.57-0.92) | 0.007 | ||
| White blood cell (1: ≥ 4000/μL) | 0.78 (0.60-1.0) | 0.061 | ||
| Hemoglobin (1: ≥ 12.5 g/dL) | 0.97 (0.74-1.3) | 0.80 | ||
| Platelet count (1: ≥ 130000/μL) | 0.31 (0.24-0.41) | < 0.0001 | 0.35 (0.27-0.46) | < 0.0001 |
| ALT (1: ≥ 40 IU/L) | 3.0 (2.3-3.8) | < 0.0001 | 2.7 (2.1-3.4) | < 0.0001 |
- Citation: Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, Morimoto Y, Hashimoto N, Sakaguchi K, Sakata T, Ando M, Makino Y, Matsumura S, Takayama H, Seki H, Nanba S, Moritou Y, Yasunaka T, Ohnishi H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K. Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol 2015; 7(19): 2220-2228
- URL: https://www.wjgnet.com/1948-5182/full/v7/i19/2220.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i19.2220